NUP37 and central nervous system cancer: NUP37 for glioma patients (grades II) suggested a significant adverse effect on the prognosis of patient only in the CGGA RNA‐seq dataset (Figure 2B), but no statistical significance was evident in the remaining two datasets (Figure 2F,J).